A day after a public showdown with activist investors Elliott Advisors, GlaxoSmithKline plc announced a significant return to neuroscience research and development, paying $700m up front for global development and commercial rights to a pair of clinical-stage antibody candidates from Alector Inc.
The progranulin-elevating drug candidates could become therapies for neurological disorders such as frontotemporal dementia, amyotrophic lateral